ArticleBMJ open diabetes research & care2025
Association between multifactorial control and excess risk of liver diseases in type 2 diabetes: a prospective cohort study.
Article in BMJ open diabetes research & care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways.Clinical science (London, England : 1979) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo examine the association of the number of controlled risk factors with the excess risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and major adverse liver outcomes (MALO) among patients with type 2 diabetes. RESEARCH DESIGN AND
methodsIn this cohort study, a total of 307,688 participants from the UK Biobank were included. Participants with baseline type 2 diabetes were categorized according to the number of risk factors within the guideline-recommended ranges (diet, smoking, drinking, exercise, sedentary behavior, body mass index, glycated hemoglobin, blood pressure, and low-density lipoprotein cholesterol).
resultsDuring a median (IQR) of 12.5 (11.8-13.2) years of follow-up, 519 (3.9%) participants with type 2 diabetes and 2718 (0.9%) participants without diabetes developed severe MASLD. Patients with type 2 diabetes had an increased risk of severe MASLD compared with participants without diabetes (HR 3.93, 95% CI 3.56 to 4.33), but the excess risk decreased stepwise with an increasing number of risk factors on target (HR (95% CI) for zero to two controlled risk factors: 5.44 (4.09 to 7.25); three controlled risk factors: 4.47 (3.59 to 5.57); four controlled risk factors: 4.16 (3.49 to 4.96); five controlled risk factors: 3.91 (3.28 to 4.66); six controlled risk factors: 3.50 (2.80 to 4.38); seven to nine controlled risk factors: 2.61 (1.92 to 3.56)). Similar patterns were observed in the analysis of MALO.
conclusionsPatients with type 2 diabetes who had more controlled risk factors showed progressively lower excess risk of severe MASLD and MALO. Comprehensive interventions targeting multiple risk factors may be associated with reduced liver lesions in patients with type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.